Anti-CD154 monoclonal antibody promotion of engraftment is CD28 dependent
| Expt . | TBI . | Recipient . | mAb . | No. chimeric . | % Donor . |
|---|---|---|---|---|---|
| 1 | 200 | +/+ | Hamster IgG | 0/10 | 0 ± 0 |
| 1 | 200 | +/+ | Anti-CD154 | 9/10 | 52 ± 224-150 |
| 1 | 200 | +/+ | Anti-CD28 | 0/10 | 0 ± 0 |
| 2 | 100 | +/+ | None | 0/10 | 0 ± 0 |
| 2 | 100 | +/+ | Anti-CD154 | 4/9 | 14 ± 174-150 |
| 2 | 100 | +/+ | Anti-CD154 + | 0/10 | 0.5 ± 14-151 |
| anti-CD28 | |||||
| 3 | 200 | +/+ | Hamster IgG | 0/10 | 0 ± 0 |
| 3 | 200 | +/+ | Anti-CD154 | 8/9 | 54 ± 214-150 |
| 3 | 200 | CD28−/− | Hamster IgG | 0/10 | 0 ± 0 |
| 3 | 200 | CD28−/− | Anti-CD154 | 0/10 | 0 ± 0 |
| Expt . | TBI . | Recipient . | mAb . | No. chimeric . | % Donor . |
|---|---|---|---|---|---|
| 1 | 200 | +/+ | Hamster IgG | 0/10 | 0 ± 0 |
| 1 | 200 | +/+ | Anti-CD154 | 9/10 | 52 ± 224-150 |
| 1 | 200 | +/+ | Anti-CD28 | 0/10 | 0 ± 0 |
| 2 | 100 | +/+ | None | 0/10 | 0 ± 0 |
| 2 | 100 | +/+ | Anti-CD154 | 4/9 | 14 ± 174-150 |
| 2 | 100 | +/+ | Anti-CD154 + | 0/10 | 0.5 ± 14-151 |
| anti-CD28 | |||||
| 3 | 200 | +/+ | Hamster IgG | 0/10 | 0 ± 0 |
| 3 | 200 | +/+ | Anti-CD154 | 8/9 | 54 ± 214-150 |
| 3 | 200 | CD28−/− | Hamster IgG | 0/10 | 0 ± 0 |
| 3 | 200 | CD28−/− | Anti-CD154 | 0/10 | 0 ± 0 |
B6 CD28+/+ (termed +/+) or CD28−/− mice were irradiated with 100 or 200 cGy TBI as indicated on day −1 and infused with 40 × 106 BALB/c BM on day 0. Antibodies were administered from day −1 through day 14. PBLs were typed for percentage donor-host at 6 weeks after BMT. Chimeric is defined as more than 3% donor PBLs. Percentage donor is defined as average percentage donor cells of all mice in the group ± 1 SD.
For abbreviations, see Table 1.
P ≤ .01 compared to hamster IgG.
P = .01 compared to anti-CD154 alone.